Halozyme Therapeutics (HALO) Tops Q3 EPS by 4c
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
Halozyme Therapeutics (NASDAQ: HALO) reported Q3 EPS of ($0.23), $0.04 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $31.9 million versus the consensus estimate of $33.86 million.
Halozyme Therapeutics sees 2016 revenue of $145-150 million, versus the consensus of $146.6 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Vera Bradley (VRA) Tops Q3 EPS by 1c; Offers Light Q4 Outlook; Enters New Licensing Agreements
- John Wiley & Sons (JW-A) Tops Q2 EPS by 9c
- SecureWorks Corp. (SCWX) Tops Q3 EPS by 6c; Guides Q4, FY17
Create E-mail Alert Related CategoriesEarnings, Guidance
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!